Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherBehavioral Pharmacology

Preclinical assessment of the abuse potential of purified botanical cannabidiol: self-administration, drug discrimination, and physical dependence

Royston A Gray, David J Heal, David R. Maguire, Lisa R. Gerak, Martin A. Javors, Sharon Smith and Charles P. France
Journal of Pharmacology and Experimental Therapeutics April 30, 2022, JPET-AR-2021-000988; DOI: https://doi.org/10.1124/jpet.121.000988
Royston A Gray
1GW Pharmaceuticals, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: france@uthscsa.edu
David J Heal
2DevelRx, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David R. Maguire
3Pharmacology, UTHSCSA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa R. Gerak
4Pharmacology, University of Texas Health Science Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin A. Javors
5Psychiatry, University of Texas HSC, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Martin A. Javors
Sharon Smith
2DevelRx, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles P. France
6Department of Pharmacology, University of Texas Health Science Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: france@uthscsa.edu
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Additional Files

  • Data Supplement

    • Supplemental Data -

      Supplementary Table S1. Statistics for baseline measures of body weight, food consumption, body temperature, and observable signs in rats treated twice daily with vehicle, CBD, diazepam, or morphine.

      Supplementary Table S2. Statistics from the analysis of change scores in rats following discontinuation of twice daily treatment with vehicle, CBD, diazepam, or morphine (Figures 4 and 5).

      Supplemental Figure 1. Plasma levels of CBD and two metabolites, 7-COOH-CBD and 7-OH-CBD, in four rhesus monkeys following i.v. administration of 0.32, 1.0, or 3.2 mg/kg CBD.

      Supplemental Figure 2. Plasma levels of CBD and three metabolites, 7-COOH-CBD 7-OH-CBD, and 6-OH-CBD, in male Sprague-Dawley rats following i.v. administration of 0.081, 0.808 and 2.67 mg/kg CBD.

      Supplemental Figure 3. Plasma levels of CBD and three metabolites, 7-COOH-CBD, 7-OH-CBD, and 6-OH-CBD, in female Lister Hooded rats following p.o. administration of 20, 75, or 150 mg/kg CBD.

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 381 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 381, Issue 2
1 May 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Preclinical assessment of the abuse potential of purified botanical cannabidiol: self-administration, drug discrimination, and physical dependence
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherBehavioral Pharmacology

Abuse potential of botanical cannabidiol

Royston A Gray, David J Heal, David R. Maguire, Lisa R. Gerak, Martin A. Javors, Sharon Smith and Charles P. France
Journal of Pharmacology and Experimental Therapeutics April 30, 2022, JPET-AR-2021-000988; DOI: https://doi.org/10.1124/jpet.121.000988

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherBehavioral Pharmacology

Abuse potential of botanical cannabidiol

Royston A Gray, David J Heal, David R. Maguire, Lisa R. Gerak, Martin A. Javors, Sharon Smith and Charles P. France
Journal of Pharmacology and Experimental Therapeutics April 30, 2022, JPET-AR-2021-000988; DOI: https://doi.org/10.1124/jpet.121.000988
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Efficacy as a determinant of hyperlocomotion by MOR ligands
  • Mu Opioid Receptor Agonist Mixtures
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics